Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 3/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 10/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 10/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 9/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678167 | 0.92 | CAPN1 (0.48) | CALCRLCAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL29678075 | 0.87 | MAPK8 (0.47) | CALCRLXIAPCAPN1NTSR2NTSR1 | |
| SCHEMBL31518676 | 0.85 | XIAP (0.49) | XIAPNTSR2NTSR1SORT1REN | |
| SCHEMBL29678210 | 0.83 | NPY1R (0.58) | CALCRLNTSR2NTSR1SORT1 | |
| SCHEMBL32677437 | 0.78 | ACE (0.44) | CALCRLCAPN1CTSBREN | |
| SCHEMBL31670650 | 0.77 | XIAP (0.45) | CALCRLXIAPCAPN1NTSR2NTSR1 | |
| SCHEMBL31518656 | 0.77 | NTSR1 (0.44) | CALCRLCAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL29576733 | 0.77 | NTSR2 (0.51) | XIAPCAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL8848776 | 0.77 | CAPN1 (0.42) | XIAPCAPN1NTSR2NTSR1SORT1 | |
| SCHEMBL30799346 | 0.76 | CAPN1 (0.54) | CALCRLXIAPCAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Molgenie GmbH (DE) | 2022-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | NPY1R, NPY2R, NPY5R | CALCRL 140/4885XIAP 1469/4885CAPN1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.